Characteristics of patients and prognostic factors of response to rEPO at week 12 according to IWG 2006 criteria (n= 403)
| . | Overall response, % . | Overall response versus nonresponse* . | |||||
|---|---|---|---|---|---|---|---|
| Univariate analysis . | Multivariate analysis† . | ||||||
| OR . | 95% CI . | P . | OR . | 95% CI . | P . | ||
| Age, y | |||||||
| Younger than 70 | 44 | 1 | — | — | 1 | — | — |
| 70 or older | 54 | 1.5 | 1.0-2.2 | .06 | 1.3 | 0.8-2.2 | .22 |
| Sex | |||||||
| Male | 46 | 1 | — | — | 1 | — | — |
| Female | 55 | 1.4 | 1.0-2.1 | .08 | 1.5 | 0.9-2.3 | .08 |
| FAB | |||||||
| RA | 61 | 1 | — | — | — | — | — |
| RARS | 48 | 0.6 | 0.4--0.9 | — | — | — | — |
| RAEB less than 10 | 43 | 0.5 | 0.3-0.8 | — | — | — | — |
| RAEB 10 or more | 23 | 0.2 | 0.1-0.5 | .001 | — | — | — |
| WHO | |||||||
| RA | 63 | 1 | — | — | 1 | — | — |
| RCMD | 61 | 0.9 | 0.5-1.9 | — | 0.9 | 0.4-2.0 | — |
| RARS | 46 | 0.5 | 0.3-1.0 | — | 0.5 | 0.2-1.0 | — |
| RCMD-RS | 50 | 0.6 | 0.3-1.3 | — | 0.7 | 0.3-1.6 | — |
| RAEB-1 | 43 | 0.5 | 0.2-0.9 | — | 0.7 | 0.3-1.4 | — |
| RAEB-2 | 23 | 0.1 | 0.0-0.4 | — | 0.7 | 0.2-3.1 | — |
| 5q− syndrome | 50 | 0.6 | 0.2-1.7 | .008 | 0.7 | 0.2-2.2 | .49 |
| Karyotype | |||||||
| Poor | 18 | 1 | — | — | — | — | — |
| Good | 53 | 4 | 1.7-9.7 | — | — | — | — |
| Intermediate | 49 | 2.7 | 0.9-7.7 | — | — | — | — |
| NA | 46 | 2.9 | 1.1-7.7 | .01 | — | — | — |
| Multilineage dysplasia | |||||||
| No | 52 | 1 | — | — | — | — | — |
| Yes | 48 | 0.9 | 0.6-1.3 | .50 | — | — | — |
| BM blasts | |||||||
| 5% or more | 38 | 1 | — | — | — | — | — |
| Less than 5% | 54 | 1.9 | 1.2-3.1 | .004 | — | — | — |
| EPO level, IU/L | |||||||
| More than 200 | 29 | 1 | — | — | 1 | — | — |
| 200 or less | 60 | 3.7 | 2.2-6.2 | — | 2.7 | 1.5-4.8 | — |
| NA | 41 | 1.7 | 0.9-3.3 | <.001 | 1.6 | 0.8-3.4 | .002 |
| IPSS subgroup | |||||||
| Int-2 and high | 16 | 1 | — | — | 1 | — | — |
| Low and int-1 | 55 | 6.4 | 2.8-14.8 | — | 4.6 | 1.5-14.0 | — |
| NA | 47 | 5.0 | 1.9-13.0 | <.001 | 3.4 | 1.0-11.2 | .02 |
| RBC transfusion before rEPO treatment | |||||||
| No | 66 | 1 | — | — | 1 | — | — |
| Yes | 37 | 0.3 | 0.2-0.4 | <.001 | 0.4 | 0.2-0.6 | <.001 |
| Addition of G-CSF | |||||||
| No | 55 | 1 | — | — | 1 | — | — |
| Yes | 41 | 0.6 | 0.4-1.0 | .08 | 0.7 | 0.4-1.1 | .12 |
| Interval from diagnosis, mo | |||||||
| 6 or more | 44 | 1 | — | — | 1 | — | — |
| Fewer than 6 | 56 | 1.7 | 1.1-2.5 | .01 | 1.6 | 1.0-2.5 | .04 |
| . | Overall response, % . | Overall response versus nonresponse* . | |||||
|---|---|---|---|---|---|---|---|
| Univariate analysis . | Multivariate analysis† . | ||||||
| OR . | 95% CI . | P . | OR . | 95% CI . | P . | ||
| Age, y | |||||||
| Younger than 70 | 44 | 1 | — | — | 1 | — | — |
| 70 or older | 54 | 1.5 | 1.0-2.2 | .06 | 1.3 | 0.8-2.2 | .22 |
| Sex | |||||||
| Male | 46 | 1 | — | — | 1 | — | — |
| Female | 55 | 1.4 | 1.0-2.1 | .08 | 1.5 | 0.9-2.3 | .08 |
| FAB | |||||||
| RA | 61 | 1 | — | — | — | — | — |
| RARS | 48 | 0.6 | 0.4--0.9 | — | — | — | — |
| RAEB less than 10 | 43 | 0.5 | 0.3-0.8 | — | — | — | — |
| RAEB 10 or more | 23 | 0.2 | 0.1-0.5 | .001 | — | — | — |
| WHO | |||||||
| RA | 63 | 1 | — | — | 1 | — | — |
| RCMD | 61 | 0.9 | 0.5-1.9 | — | 0.9 | 0.4-2.0 | — |
| RARS | 46 | 0.5 | 0.3-1.0 | — | 0.5 | 0.2-1.0 | — |
| RCMD-RS | 50 | 0.6 | 0.3-1.3 | — | 0.7 | 0.3-1.6 | — |
| RAEB-1 | 43 | 0.5 | 0.2-0.9 | — | 0.7 | 0.3-1.4 | — |
| RAEB-2 | 23 | 0.1 | 0.0-0.4 | — | 0.7 | 0.2-3.1 | — |
| 5q− syndrome | 50 | 0.6 | 0.2-1.7 | .008 | 0.7 | 0.2-2.2 | .49 |
| Karyotype | |||||||
| Poor | 18 | 1 | — | — | — | — | — |
| Good | 53 | 4 | 1.7-9.7 | — | — | — | — |
| Intermediate | 49 | 2.7 | 0.9-7.7 | — | — | — | — |
| NA | 46 | 2.9 | 1.1-7.7 | .01 | — | — | — |
| Multilineage dysplasia | |||||||
| No | 52 | 1 | — | — | — | — | — |
| Yes | 48 | 0.9 | 0.6-1.3 | .50 | — | — | — |
| BM blasts | |||||||
| 5% or more | 38 | 1 | — | — | — | — | — |
| Less than 5% | 54 | 1.9 | 1.2-3.1 | .004 | — | — | — |
| EPO level, IU/L | |||||||
| More than 200 | 29 | 1 | — | — | 1 | — | — |
| 200 or less | 60 | 3.7 | 2.2-6.2 | — | 2.7 | 1.5-4.8 | — |
| NA | 41 | 1.7 | 0.9-3.3 | <.001 | 1.6 | 0.8-3.4 | .002 |
| IPSS subgroup | |||||||
| Int-2 and high | 16 | 1 | — | — | 1 | — | — |
| Low and int-1 | 55 | 6.4 | 2.8-14.8 | — | 4.6 | 1.5-14.0 | — |
| NA | 47 | 5.0 | 1.9-13.0 | <.001 | 3.4 | 1.0-11.2 | .02 |
| RBC transfusion before rEPO treatment | |||||||
| No | 66 | 1 | — | — | 1 | — | — |
| Yes | 37 | 0.3 | 0.2-0.4 | <.001 | 0.4 | 0.2-0.6 | <.001 |
| Addition of G-CSF | |||||||
| No | 55 | 1 | — | — | 1 | — | — |
| Yes | 41 | 0.6 | 0.4-1.0 | .08 | 0.7 | 0.4-1.1 | .12 |
| Interval from diagnosis, mo | |||||||
| 6 or more | 44 | 1 | — | — | 1 | — | — |
| Fewer than 6 | 56 | 1.7 | 1.1-2.5 | .01 | 1.6 | 1.0-2.5 | .04 |